SEC EDGARAUG 211 min read$ILMN

Meister Keith A. sold $145.6M of ILMN (indirect holdings)

Meister Keith A. sold 679,574 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $214.19 ($202.37–$220.13, $145.56M total) across 28 trades over 2026-08-19 to 2026-08-21.

Original reporting

SEC EDGAR · Meister Keith A.

Published Aug 21, 2026, 11:42 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 22, 2026, 12:06 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Bearish

high confidence

Mentioned

$ILMN

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNBearishHigh

Why it matters

The sizable divestiture by a director may trigger short‑term sell pressure and influence analyst sentiment.

Market read

Large insider sale provides fresh material for traders; likely short‑term downside bias.

What to watch

Potential tax planning or diversification motives not disclosed.

Relevance 8/10Novelty 9/10Timing: post‑market Aug 21

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBearishHigh confidence

Context

Director Meister Keith A. sold $145.6M (679,574 shares) of Illumina in open‑market trades.

Expected impact

Short‑term downward pressure on ILMN price.

Evidence & confidence

Sale size exceeds $100M and represents a significant portion of holdings, likely signaling reduced confidence.

Market effects

Sector

May raise concerns for the genomics/diagnostics sector about insider confidence.

Regional

Limited to US biotech market; no broader regional effect.

Global

Minimal global impact beyond Illumina investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

company
Illumina, Inc.
US‑listed genomics and diagnostics firm (NASDAQ: ILMN).
person
Meister Keith A.
Director of Illumina.

Read at source ← All news

SEP 18

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

scanx.trade3 min

SEP 18

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

benzinga.com3 min

SEP 17

$ILMNMedAI 9/10

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher

Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.

cnbc.com3 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

SEP 16

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

yahoo.com3 min

SEP 15

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv

stockstotrade.com2 min